CLINICAL TRIAL / NCT05019976

Radiation Dose Study for Relapsed/Refractory Hodgkin/Non-Hodgkin Lymphoma

  • Interventional
  • Recruiting
  • NCT05019976

An i3+3 Phase I Dose-per-Fraction Escalation Trial for Relapsed/Refractory Hodgkin/Non-Hodgkin Lymphoma

This study focuses on using shortened courses of radiation for participants with relapsed/refractory Hodgkin/Non-Hodgkin lymphoma. Treatment radiation over 5-6 weeks is often standard of care for many people with lymphoma, but doctors leading this study aim to find out if using radiation for a shorter period of time can be safe for treating lymphoma and if so, what is the safest shortened dose of radiation for participants.